ondansetron has been researched along with Disease Models, Animal in 71 studies
Ondansetron: A competitive serotonin type 3 receptor antagonist. It is effective in the treatment of nausea and vomiting caused by cytotoxic chemotherapy drugs, including cisplatin, and has reported anxiolytic and neuroleptic properties.
Disease Models, Animal: Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To determine the minimally effective dose of cannabidiolic acid (CBDA) that effectively reduces lithium chloride (LiCl)-induced conditioned gaping reactions (nausea-induced behaviour) in rats and to determine if these low systemic doses of CBDA (5-0." | 7.79 | Effect of low doses of cannabidiolic acid and ondansetron on LiCl-induced conditioned gaping (a model of nausea-induced behaviour) in rats. ( Parker, LA; Rock, EM, 2013) |
| "The effect of central administration of ondansetron, a 5-hydroxytryptamine-3 (5-HT3) receptor antagonist on gastric secretion and gastric cytoprotection was evaluated using four different models of gastric ulcers and cysteamine induced duodenal ulcer." | 7.75 | Effect of central administration of ondansetron, a 5-hydroxytryptamine-3 receptor antagonist on gastric and duodenal ulcers. ( Asad, M; Dhamanigi, SS; Prasad, VS; Ramesh, ST, 2009) |
| "Not all neuropathic pain patients gain relief from current therapies that include the anticonvulsant, gabapentin, thought to modulate calcium channel function." | 7.73 | Spinal-supraspinal serotonergic circuits regulating neuropathic pain and its treatment with gabapentin. ( Dickenson, AH; Hunt, SP; Rahman, W; Rygh, LJ; Suzuki, R; Webber, M, 2005) |
| "We investigated the emetic effects of cisplatin and methotrexate in dogs, the effects of ondansetron on cisplatin-induced vomiting, and the effects of ondansetron, dexamethasone and a combination of the two on the vomiting induced by methotrexate." | 7.70 | Methotrexate produces delayed emesis in dogs: a potential model of delayed emesis induced by chemotherapy. ( Fukui, H; Yamamoto, M, 1999) |
| "The profile of action of ondansetron was assessed in a novel animal model of anxiety." | 7.69 | Antianxiety profile of ondansetron, a selective 5-HT3 antagonist, in a novel animal model. ( Kulkarni, SK; Roychoudhury, M, 1997) |
| "Pretreatment with ondansetron inhibited cisplatin-induced kaolin intake." | 5.29 | Pica in rats is analogous to emesis: an animal model in emesis research. ( Hasegawa, S; Matsunaga, T; Morita, M; Takeda, N, 1993) |
| "Optical mapping was performed in rabbit hearts with pacing-induced heart failure (HF) and in normal hearts before and after ondansetron (100 nM) infusion." | 3.96 | Effects of ondansetron on apamin-sensitive small conductance calcium-activated potassium currents in pacing-induced failing rabbit hearts. ( Chen, M; Chen, PS; Chen, Z; Everett, TH; Kamp, NJ; Lin, SF; Rubart-von der Lohe, M; Shen, C; Tian, Z; Wang, Z; Wu, AZ; Xu, D; Yang, N; Yin, D, 2020) |
| "During observation period,compared with model group,the frequency cisplatin induced retching and vomiting was significantly reduced by Ju-Pi-Tang in high- and mid-dose groups, during the 0-24 h acute period, the number of retching of Ju-Pi-Tang in high-dose group was decreased more than aprepitant group, during the 24-72 h delayed period, the number of both retching and vomiting was decreased more than ondansetron group, after 72 h of cisplatin administration, compared with model group, the grey levels of c-fos and substance P expression in distal ileum and brain tissues of Ju-Pi-Tang groups were higher significantly." | 3.81 | [Effect of Ju-Pi-Tang on Cisplatin-induced Emetic Model in Minks]. ( Liu, RR; Liu, ZT; Yang, YL; Yang, ZH; Yue, W, 2015) |
| " Facilitation of pain behaviour induced by GAL in the DMH was reversed by lidocaine in the DRt and by ondansetron, a 5HT3R antagonist, in the spinal cord." | 3.81 | Galanin-Mediated Behavioural Hyperalgesia from the Dorsomedial Nucleus of the Hypothalamus Involves Two Independent Descending Pronociceptive Pathways. ( Almeida, A; Amorim, D; Pertovaara, A; Pinto-Ribeiro, F; Viisanen, H; Wei, H, 2015) |
| "To determine the minimally effective dose of cannabidiolic acid (CBDA) that effectively reduces lithium chloride (LiCl)-induced conditioned gaping reactions (nausea-induced behaviour) in rats and to determine if these low systemic doses of CBDA (5-0." | 3.79 | Effect of low doses of cannabidiolic acid and ondansetron on LiCl-induced conditioned gaping (a model of nausea-induced behaviour) in rats. ( Parker, LA; Rock, EM, 2013) |
| "We found that paracetamol 100 mg kg⁻¹ blocked the development of hyperalgesia and allodynia after fracture pain and ondansetron did not modify the antinociceptive effect of paracetamol in this model." | 3.77 | Ondansetron does not block paracetamol-induced analgesia in a mouse model of fracture pain. ( Fourcade, O; Girolami, JP; Mazoit, JX; Minville, V; Tack, I, 2011) |
| "The effect of central administration of ondansetron, a 5-hydroxytryptamine-3 (5-HT3) receptor antagonist on gastric secretion and gastric cytoprotection was evaluated using four different models of gastric ulcers and cysteamine induced duodenal ulcer." | 3.75 | Effect of central administration of ondansetron, a 5-hydroxytryptamine-3 receptor antagonist on gastric and duodenal ulcers. ( Asad, M; Dhamanigi, SS; Prasad, VS; Ramesh, ST, 2009) |
| "Cocaine abusers remain vulnerable to drug craving and relapse for many years after abstinence is achieved." | 3.74 | Reversal of cocaine-induced behavioral sensitization and associated phosphorylation of the NR2B and GluR1 subunits of the NMDA and AMPA receptors. ( Davidson, C; Ellinwood, EH; Lazarus, C; Lee, TH; Wetsel, WC; Zhang, X, 2007) |
| " However, retching and vomiting were significantly inhibited by pretreatment with ondansetron and metoclopramide in cisplatin and copper sulfate groups (P=0." | 3.73 | Value of mink vomit model in study of anti-emetic drugs. ( Liu, ZT; Wang, L; Yang, ZH; Yue, W; Zhang, F, 2006) |
| "Not all neuropathic pain patients gain relief from current therapies that include the anticonvulsant, gabapentin, thought to modulate calcium channel function." | 3.73 | Spinal-supraspinal serotonergic circuits regulating neuropathic pain and its treatment with gabapentin. ( Dickenson, AH; Hunt, SP; Rahman, W; Rygh, LJ; Suzuki, R; Webber, M, 2005) |
| " Cisplatin, apomorphine, copper sulfate and X-radiation were used to establish vomiting model." | 3.72 | [A new vomiting animal model--mink]. ( Fang, X; Liu, YX; Minami, M; Wang, L; Yue, W; Zhang, F, 2003) |
| "We demonstrated that both eusatron and ondansetron effectively abolished the emesis normally induced by 2-Gy doses of either 60Co gamma or neutron:gamma, mixed-field irradiation, the latter with a neutron-to-total dose ratio (Dn/Dt) of 0." | 3.70 | 5-HT3 receptor antagonists ameliorate emesis in the ferret evoked by neutron or proton radiation. ( King, GL; Rabin, BM; Weatherspoon, JK, 1999) |
| "We investigated the emetic effects of cisplatin and methotrexate in dogs, the effects of ondansetron on cisplatin-induced vomiting, and the effects of ondansetron, dexamethasone and a combination of the two on the vomiting induced by methotrexate." | 3.70 | Methotrexate produces delayed emesis in dogs: a potential model of delayed emesis induced by chemotherapy. ( Fukui, H; Yamamoto, M, 1999) |
| "The profile of action of ondansetron was assessed in a novel animal model of anxiety." | 3.69 | Antianxiety profile of ondansetron, a selective 5-HT3 antagonist, in a novel animal model. ( Kulkarni, SK; Roychoudhury, M, 1997) |
| "The effects of the 5-HT3 receptor antagonists, zacopride, ondansetron and ICS 205-930, were investigated in an animal model of depression, the learned helplessness test." | 3.68 | 5-HT3 receptor antagonists reverse helpless behaviour in rats. ( Gozlan, H; Martin, P; Puech, AJ, 1992) |
| "The antiemetic activity of DAU 6215, a novel antagonist of 5-HT3 receptors, was investigated in animal models of cytotoxic treatment-evoked emesis and compared with the antiemetic activity of ondansetron and metoclopramide." | 3.68 | Antiemetic activity of the new 5-HT3 antagonist DAU 6215 in animal models of cancer chemotherapy and radiation. ( Algate, DR; Bonali, P; Donetti, A; Micheletti, R; Montagna, E; Nicola, M; Rimoldi, EM; Sagrada, A; Schiantarelli, P; Turconi, M, 1991) |
| "5-Hydroxytryptophan has the opposite effect exacerbating the behavioural response to the aversive situation." | 2.38 | The pharmacology of the 5-HT4 receptor. ( Costall, B; Naylor, RJ, 1993) |
| "Pain and inflammation are complex clinical conditions that are present in a wide variety of disorders." | 1.48 | LASSBio-1586, an N-acylhydrazone derivative, attenuates nociceptive behavior and the inflammatory response in mice. ( Alencar Filho, EB; Almeida, JRGDS; Barreiro, EJL; Diniz, TC; Lavor, ÉM; Lima, LM; Lima-Saraiva, SRG; Mendes, RL; Oliveira Júnior, RG; Silva, JC; Silva, MGE; Soares, JMD, 2018) |
| "After confirming hyperalgesia, male mice were treated with αTPN-βCD (25, 50 or 100 mg/kg; p." | 1.43 | α-Terpineol, a monoterpene alcohol, complexed with β-cyclodextrin exerts antihyperalgesic effect in animal model for fibromyalgia aided with docking study. ( Almeida, JR; Araújo, AA; Araújo-Filho, HG; Brito, RG; Carvalho, YM; Menezes, PP; Oliveira, MG; Quintans, JS; Quintans-Júnior, LJ; Santos, PL; Scotti, L; Scotti, MT; Serafini, MR; Shanmugam, S; Silva, JC; Thangaraj, P, 2016) |
| "PTZ-kindled mice showed high seizure activity, hippocampal neuronal loss, and expression of growth-associated phosphoprotein (GAP-43) compared with saline-treated mice." | 1.42 | Fluvoxamine alleviates seizure activity and downregulates hippocampal GAP-43 expression in pentylenetetrazole-kindled mice: role of 5-HT3 receptors. ( Alhaj, MW; Moustafa, YM; Zaitone, SA, 2015) |
| " In addition to acute treatment (1 day), the effects of chronic administration (10 days) were examined in an attempt to model human treatment approaches." | 1.40 | Acute and chronic administration of a low-dose combination of topiramate and ondansetron reduces ethanol's reinforcing effects in male alcohol preferring (P) rats. ( Bond, CW; Johnson, BA; Lycas, MD; Lynch, WJ; Moore, CF, 2014) |
| "Neuropathic pain is frequently characterized by spontaneous pain (ie, pain at rest) and, in some cases, by cold- and touch-induced allodynia." | 1.39 | Descending facilitation maintains long-term spontaneous neuropathic pain. ( De Felice, M; Guo, W; King, T; Ossipov, MH; Porreca, F; Wang, R, 2013) |
| "Ondansetron is an antagonist of 5-HT3 receptors mostly used as an antiemetic yet known to modulate metabolism and appetite." | 1.38 | Differential effects of 5-HT3 receptor antagonist on lipid profile in spontaneously hypertensive rat and chromosome 8 congenic strain. ( Kren, V; Krenova, D; Krupkova, M; Liska, F; Seda, O; Sedova, L, 2012) |
| "The transition to menopause is associated with an increased risk of depressed mood." | 1.38 | Effects of diphenyl diselenide on depressive-like behavior in ovariectomized mice submitted to subchronic stress: involvement of the serotonergic system. ( Bazanella Sampaio, T; Mozzaquatro Gai, B; Nogueira, CW; Pinton, S; Trevisan da Rocha, J; Zeni, G, 2012) |
| "Alcohol dependence is the third leading cause of preventable death in the USA." | 1.37 | Severity of drinking as a predictor of efficacy of the combination of ondansetron and topiramate in rat models of ethanol consumption and relapse. ( Bond, C; Breslin, FJ; Johnson, BA; Lynch, WJ, 2011) |
| "Ondansetron is a 5-HT3 receptor antagonist with potent antiemetic, analgesic, and antiphlogistic effects." | 1.37 | Ondansetron attenuates hepatic injury via p38 MAPK-dependent pathway in a rat haemorrhagic shock model. ( Liu, FC; Liu, FW; Yu, HP, 2011) |
| "The SP-induced hyperalgesia was both GABA(A) and NMDA receptor-dependent after pre- and post-treatment with selective antagonists at the spinal level." | 1.36 | Spinal cord mechanisms mediating behavioral hyperalgesia induced by neurokinin-1 tachykinin receptor activation in the rostral ventromedial medulla. ( Dubner, R; Guo, W; Lagraize, SC; Ren, K; Wei, F; Yang, K, 2010) |
| " Dose-response curves were also obtained with tramadol combined with ondansetron or droperidol at 1:1 fixed ratios." | 1.33 | Interaction between tramadol and two anti-emetics on nociception and gastrointestinal transit in mice. ( Dürsteler, C; Fernandez, V; Mases, A; Pol, O; Puig, MM, 2006) |
| "The effects of seizures were observed to a much larger extent in malformed than in normal brain tissue." | 1.33 | Determinants of drug brain uptake in a rat model of seizure-associated malformations of cortical development. ( Bassanini, S; Battaglia, G; Caccia, S; Chimenti, S; Gagliardi, B; Guiso, G; Marchi, N; Noé, F; Ravizza, T; Rizzi, M; Vezzani, A, 2006) |
| "The ondansetron treated rats showed only a non-significant decrease in break point." | 1.31 | Ondansetron given in the acute withdrawal from a repeated cocaine sensitization dosing regimen reverses the expression of sensitization and inhibits self-administration. ( Davidson, C; Ellinwood, EH; Lee, TH; Xiong, Z, 2002) |
| "Alosetron (Lotronex) is a serotonin subtype 3 (5-HT3) receptor antagonist that alleviates symptoms of irritable bowel syndrome (IBS) in female patients." | 1.31 | Effects of alosetron on spontaneous migrating motor complexes in murine small and large bowel in vitro. ( Bush, TG; Sanders, KM; Smith, TK; Spencer, NJ; Watters, N, 2001) |
| "No vomiting was observed between the 16th and 18th hr." | 1.29 | The piglet as a suitable animal model for studying the delayed phase of cisplatin-induced emesis. ( Blower, P; Grélot, L; Milano, S; Romain, D, 1995) |
| ") displaced the 5-HT dose-response curve to the right, with apparent DR2 values of 0." | 1.29 | Serotonin (5-HT)3-receptor antagonism of 4,5,6,7-tetrahydrobenzimidazole derivatives against 5-HT-induced bradycardia in anesthetized rats. ( Honda, K; Ito, H; Kamato, T; Miyata, K; Nishida, A; Tsutsumi, R; Yamano, M; Yuki, H, 1994) |
| "Pretreatment with ondansetron inhibited cisplatin-induced kaolin intake." | 1.29 | Pica in rats is analogous to emesis: an animal model in emesis research. ( Hasegawa, S; Matsunaga, T; Morita, M; Takeda, N, 1993) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 15 (21.13) | 18.2507 |
| 2000's | 20 (28.17) | 29.6817 |
| 2010's | 29 (40.85) | 24.3611 |
| 2020's | 7 (9.86) | 2.80 |
| Authors | Studies |
|---|---|
| Kishibayashi, N | 1 |
| Miwa, Y | 1 |
| Hayashi, H | 1 |
| Ishii, A | 1 |
| Ichikawa, S | 1 |
| Nonaka, H | 1 |
| Yokoyama, T | 1 |
| Suzuki, F | 1 |
| Manning, DD | 1 |
| Cioffi, CL | 1 |
| Usyatinsky, A | 1 |
| Fitzpatrick, K | 1 |
| Masih, L | 1 |
| Guo, C | 1 |
| Zhang, Z | 1 |
| Choo, SH | 1 |
| Sikkander, MI | 1 |
| Ryan, KN | 1 |
| Naginskaya, J | 1 |
| Hassler, C | 1 |
| Dobritsa, S | 1 |
| Wierschke, JD | 1 |
| Earley, WG | 1 |
| Butler, AS | 1 |
| Brady, CA | 1 |
| Barnes, NM | 1 |
| Cohen, ML | 1 |
| Guzzo, PR | 1 |
| Abrams, RPM | 1 |
| Yasgar, A | 1 |
| Teramoto, T | 1 |
| Lee, MH | 1 |
| Dorjsuren, D | 1 |
| Eastman, RT | 1 |
| Malik, N | 1 |
| Zakharov, AV | 1 |
| Li, W | 1 |
| Bachani, M | 1 |
| Brimacombe, K | 1 |
| Steiner, JP | 1 |
| Hall, MD | 1 |
| Balasubramanian, A | 1 |
| Jadhav, A | 1 |
| Padmanabhan, R | 1 |
| Simeonov, A | 1 |
| Nath, A | 1 |
| Kwan, C | 1 |
| Lévesque, C | 1 |
| Bédard, D | 1 |
| Frouni, I | 1 |
| Yesuf, JM | 1 |
| Hamadjida, A | 1 |
| Lévesque, D | 1 |
| Clarke, PB | 1 |
| Huot, P | 1 |
| Yin, D | 1 |
| Yang, N | 1 |
| Tian, Z | 1 |
| Wu, AZ | 1 |
| Xu, D | 1 |
| Chen, M | 1 |
| Kamp, NJ | 1 |
| Wang, Z | 1 |
| Shen, C | 1 |
| Chen, Z | 1 |
| Lin, SF | 1 |
| Rubart-von der Lohe, M | 1 |
| Chen, PS | 1 |
| Everett, TH | 1 |
| Sahbaie, P | 1 |
| Irvine, KA | 1 |
| Liang, DY | 1 |
| Shi, X | 1 |
| Clark, JD | 1 |
| Zirak, MR | 1 |
| Karimi, G | 1 |
| Rahimian, R | 1 |
| Jafarian, AH | 1 |
| Hayes, AW | 1 |
| Mehri, S | 1 |
| Nascimento, EB | 1 |
| Romero, TRL | 1 |
| Dutra, MMGB | 1 |
| Fiebich, BL | 1 |
| Duarte, IDG | 1 |
| Coelho, MM | 1 |
| Sasaki, M | 1 |
| Kamiya, Y | 1 |
| Bamba, K | 1 |
| Onishi, T | 1 |
| Matsuda, K | 1 |
| Kohno, T | 1 |
| Kurabe, M | 1 |
| Furutani, K | 1 |
| Yanagimura, H | 1 |
| Goda, M | 1 |
| Kanda, M | 1 |
| Yoshioka, T | 1 |
| Yoshida, A | 1 |
| Murai, Y | 1 |
| Zamami, Y | 1 |
| Aizawa, F | 1 |
| Niimura, T | 1 |
| Hamano, H | 1 |
| Okada, N | 1 |
| Yagi, K | 1 |
| Chuma, M | 1 |
| Izawa-Ishizawa, Y | 1 |
| Ishizawa, K | 1 |
| Murozono, M | 1 |
| Miyashita, R | 1 |
| Takeda, A | 1 |
| Ynagita, K | 1 |
| Sato, E | 1 |
| Ogiwara, Y | 1 |
| Giorno, TBS | 1 |
| Moreira, IGDS | 1 |
| Rezende, CM | 1 |
| Fernandes, PD | 1 |
| Silva, JC | 2 |
| Oliveira Júnior, RG | 1 |
| Silva, MGE | 1 |
| Lavor, ÉM | 1 |
| Soares, JMD | 1 |
| Lima-Saraiva, SRG | 1 |
| Diniz, TC | 1 |
| Mendes, RL | 1 |
| Alencar Filho, EB | 1 |
| Barreiro, EJL | 1 |
| Lima, LM | 1 |
| Almeida, JRGDS | 1 |
| Patel, R | 2 |
| Dickenson, AH | 4 |
| Rock, EM | 1 |
| Parker, LA | 4 |
| Wang, R | 1 |
| King, T | 1 |
| De Felice, M | 1 |
| Guo, W | 2 |
| Ossipov, MH | 1 |
| Porreca, F | 1 |
| Bektas, N | 1 |
| Arslan, R | 1 |
| Ozturk, Y | 1 |
| Moore, CF | 1 |
| Lycas, MD | 1 |
| Bond, CW | 1 |
| Johnson, BA | 2 |
| Lynch, WJ | 2 |
| Alhaj, MW | 1 |
| Zaitone, SA | 1 |
| Moustafa, YM | 1 |
| Bétry, C | 1 |
| Overstreet, D | 1 |
| Haddjeri, N | 1 |
| Pehrson, AL | 1 |
| Bundgaard, C | 1 |
| Sanchez, C | 1 |
| Mørk, A | 1 |
| Ostadhadi, S | 1 |
| Kordjazy, N | 1 |
| Haj-Mirzaian, A | 1 |
| Mansouri, P | 1 |
| Dehpour, AR | 1 |
| Bannister, K | 1 |
| Goncalves, L | 1 |
| Townson, L | 1 |
| Liu, RR | 1 |
| Yang, ZH | 2 |
| Yang, YL | 1 |
| Liu, ZT | 2 |
| Yue, W | 3 |
| Amorim, D | 1 |
| Viisanen, H | 1 |
| Wei, H | 1 |
| Almeida, A | 1 |
| Pertovaara, A | 1 |
| Pinto-Ribeiro, F | 1 |
| Sumaya, IC | 1 |
| Bailey, D | 1 |
| Catlett, SL | 1 |
| Oliveira, MG | 1 |
| Brito, RG | 1 |
| Santos, PL | 1 |
| Araújo-Filho, HG | 1 |
| Quintans, JS | 1 |
| Menezes, PP | 1 |
| Serafini, MR | 1 |
| Carvalho, YM | 1 |
| Almeida, JR | 1 |
| Scotti, L | 1 |
| Scotti, MT | 1 |
| Shanmugam, S | 1 |
| Thangaraj, P | 1 |
| Araújo, AA | 1 |
| Quintans-Júnior, LJ | 1 |
| Zarzana, EC | 1 |
| Basso, AS | 1 |
| Costa-Pinto, FA | 1 |
| Palermo-Neto, J | 1 |
| Ramesh, ST | 1 |
| Asad, M | 1 |
| Dhamanigi, SS | 1 |
| Prasad, VS | 1 |
| Real, C | 1 |
| Seif, I | 1 |
| Adrien, J | 1 |
| Escourrou, P | 1 |
| Dergacheva, O | 1 |
| Kamendi, H | 1 |
| Wang, X | 1 |
| Pinol, RA | 1 |
| Frank, J | 1 |
| Gorini, C | 1 |
| Jameson, H | 1 |
| Lovett-Barr, MR | 1 |
| Mendelowitz, D | 1 |
| Milot, MR | 1 |
| Plamondon, H | 1 |
| Debnath, S | 1 |
| Biswas, D | 1 |
| Ray, K | 1 |
| Guha, D | 1 |
| Lagraize, SC | 1 |
| Yang, K | 1 |
| Wei, F | 1 |
| Ren, K | 1 |
| Dubner, R | 1 |
| Minville, V | 1 |
| Fourcade, O | 1 |
| Mazoit, JX | 1 |
| Girolami, JP | 1 |
| Tack, I | 1 |
| Liu, FC | 1 |
| Liu, FW | 1 |
| Yu, HP | 1 |
| Bond, C | 1 |
| Breslin, FJ | 1 |
| Tuerke, KJ | 1 |
| Winters, BD | 1 |
| Heinl, C | 1 |
| Drdla-Schutting, R | 1 |
| Xanthos, DN | 1 |
| Sandkühler, J | 1 |
| Trevisan da Rocha, J | 1 |
| Mozzaquatro Gai, B | 1 |
| Pinton, S | 1 |
| Bazanella Sampaio, T | 1 |
| Nogueira, CW | 1 |
| Zeni, G | 1 |
| Hayashida, K | 1 |
| Kimura, M | 1 |
| Yoshizumi, M | 1 |
| Hobo, S | 1 |
| Obata, H | 1 |
| Eisenach, JC | 1 |
| Krupkova, M | 1 |
| Sedova, L | 1 |
| Liska, F | 1 |
| Krenova, D | 1 |
| Kren, V | 1 |
| Seda, O | 1 |
| Davidson, C | 2 |
| Lee, TH | 2 |
| Xiong, Z | 1 |
| Ellinwood, EH | 2 |
| Zhang, F | 2 |
| Wang, L | 2 |
| Fang, X | 1 |
| Liu, YX | 1 |
| Minami, M | 1 |
| Aung, HH | 1 |
| Mehendale, SR | 1 |
| Xie, JT | 1 |
| Moss, J | 1 |
| Yuan, CS | 1 |
| Suzuki, R | 1 |
| Rahman, W | 1 |
| Rygh, LJ | 1 |
| Webber, M | 1 |
| Hunt, SP | 1 |
| Kwiatkowska, M | 1 |
| Mechoulam, R | 1 |
| Donovan-Rodriguez, T | 1 |
| Urch, CE | 1 |
| Dürsteler, C | 1 |
| Mases, A | 1 |
| Fernandez, V | 1 |
| Pol, O | 1 |
| Puig, MM | 1 |
| Heilig, M | 1 |
| Egli, M | 1 |
| Limebeer, CL | 1 |
| Hall, G | 1 |
| Zhang, X | 1 |
| Lazarus, C | 1 |
| Wetsel, WC | 1 |
| Marchi, N | 1 |
| Guiso, G | 1 |
| Caccia, S | 1 |
| Rizzi, M | 1 |
| Gagliardi, B | 1 |
| Noé, F | 1 |
| Ravizza, T | 1 |
| Bassanini, S | 1 |
| Chimenti, S | 1 |
| Battaglia, G | 1 |
| Vezzani, A | 1 |
| Nakade, Y | 1 |
| Fukuda, H | 1 |
| Iwa, M | 1 |
| Tsukamoto, K | 1 |
| Yanagi, H | 1 |
| Yamamura, T | 1 |
| Mantyh, C | 1 |
| Pappas, TN | 1 |
| Takahashi, T | 1 |
| Milano, S | 1 |
| Blower, P | 1 |
| Romain, D | 1 |
| Grélot, L | 1 |
| Langer, JC | 1 |
| Liebman, SM | 1 |
| Monk, PK | 1 |
| Pelletier, GJ | 1 |
| Rudd, JA | 1 |
| Naylor, RJ | 2 |
| Yamano, M | 1 |
| Kamato, T | 1 |
| Nishida, A | 1 |
| Ito, H | 1 |
| Yuki, H | 1 |
| Tsutsumi, R | 1 |
| Honda, K | 1 |
| Miyata, K | 1 |
| Shepherd, JK | 1 |
| Grewal, SS | 1 |
| Fletcher, A | 1 |
| Bill, DJ | 1 |
| Dourish, CT | 1 |
| Costall, B | 1 |
| Takeda, N | 2 |
| Hasegawa, S | 1 |
| Morita, M | 1 |
| Matsunaga, T | 1 |
| Kacker, V | 1 |
| Gupta, YK | 1 |
| Roychoudhury, M | 1 |
| Kulkarni, SK | 1 |
| Grøndahl, ML | 1 |
| Jensen, GM | 1 |
| Nielsen, CG | 1 |
| Skadhauge, E | 1 |
| Olsen, JE | 1 |
| Hansen, MB | 1 |
| King, GL | 1 |
| Rabin, BM | 1 |
| Weatherspoon, JK | 1 |
| Fukui, H | 1 |
| Yamamoto, M | 1 |
| Veasey, SC | 1 |
| Chachkes, J | 1 |
| Fenik, P | 1 |
| Hendricks, JC | 1 |
| Bush, TG | 1 |
| Spencer, NJ | 1 |
| Watters, N | 1 |
| Sanders, KM | 1 |
| Smith, TK | 1 |
| Yamamoto, K | 1 |
| Matsunaga, S | 1 |
| Matsui, M | 1 |
| Yamatodani, A | 1 |
| Martin, P | 1 |
| Gozlan, H | 1 |
| Puech, AJ | 1 |
| Sagrada, A | 1 |
| Turconi, M | 1 |
| Bonali, P | 1 |
| Schiantarelli, P | 1 |
| Micheletti, R | 1 |
| Montagna, E | 1 |
| Nicola, M | 1 |
| Algate, DR | 1 |
| Rimoldi, EM | 1 |
| Donetti, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Pain Phenotyping of Patients With Bone Cancer Pain[NCT03908853] | 70 participants (Anticipated) | Observational | 2019-02-05 | Recruiting | |||
| Effects of Corticotropin-Releasing Hormone Receptor 1 (CRH1) Antagonism on Stress-Induced Craving in Alcoholic Women With High Anxiety: an Experimental Medicine Study[NCT01187511] | Phase 2 | 44 participants (Actual) | Interventional | 2010-01-31 | Completed | ||
| Corticotropin-Releasing Hormone Receptor 1 (CRH1) Antagonism in Anxious Alcoholics[NCT01227980] | Phase 2 | 70 participants (Actual) | Interventional | 2010-10-31 | Completed | ||
| Modulation of Pharmacologically Induced Alcohol Craving in Recently Detoxified Alcoholics[NCT00605904] | Phase 2 | 37 participants (Actual) | Interventional | 2008-01-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01187511)
Timeframe: 15 minutes after the beginning of script presentation, which occurred on Day 25, 26, or 27 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| GSK561679 | 11.6932 |
| Placebo | 14.6126 |
Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01187511)
Timeframe: 15 minutes prior to the beginning of script presentation, which occurred on Day 25, 26, or 27 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| GSK561679 | 8.7646 |
| Placebo | 10.413 |
Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01187511)
Timeframe: 30 minutes after the beginning of script presentation, which occurred on Day 25, 26, or 27 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| GSK561679 | 11.4075 |
| Placebo | 13.0412 |
Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01187511)
Timeframe: 45 minutes after the beginning of script presentation, which occurred on Day 25, 26, or 27 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| GSK561679 | 9.6218 |
| Placebo | 12.1841 |
Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01187511)
Timeframe: 5 minutes after the beginning of script presentation, which occurred on Day 25, 26, or 27 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| GSK561679 | 13.9789 |
| Placebo | 15.946 |
Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01187511)
Timeframe: 60 minutes after the beginning of script presentation, which occurred on Day 25, 26, or 27 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| GSK561679 | 9.9075 |
| Placebo | 12.1841 |
Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01187511)
Timeframe: 75 minutes after the beginning of script presentation, which occurred on Day 25, 26, or 27 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| GSK561679 | 9.6218 |
| Placebo | 11.6603 |
Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01187511)
Timeframe: 90 minutes after the beginning of script presentation, which occurred on Day 25, 26, or 27 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| GSK561679 | 8.9075 |
| Placebo | 13.1841 |
Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01187511)
Timeframe: 15 minutes after the beginning of script presentation, which occurred on Day 25, 26, or 27 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| GSK561679 | 12.1376 |
| Placebo | 13.1086 |
Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01187511)
Timeframe: 15 minutes prior to the beginning of script presentation, which occurred on Day 25, 26, or 27 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| GSK561679 | 9.7805 |
| Placebo | 10.6194 |
Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01187511)
Timeframe: 30 minutes after the beginning of script presentation, which occurred on Day 25, 26, or 27 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| GSK561679 | 11.7091 |
| Placebo | 13.1432 |
Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01187511)
Timeframe: 45 minutes after the beginning of script presentation, which occurred on Day 25, 26, or 27 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| GSK561679 | 11.3519 |
| Placebo | 12.1432 |
Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01187511)
Timeframe: 5 minutes after the beginning of script presentation, which occurred on Day 25, 26, or 27 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| GSK561679 | 14.1376 |
| Placebo | 16.9051 |
Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01187511)
Timeframe: 60 minutes after the beginning of script presentation, which occurred on Day 25, 26, or 27 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| GSK561679 | 11.2805 |
| Placebo | 12.0956 |
Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01187511)
Timeframe: 75 minutes after the beginning of script presentation, which occurred on Day 25, 26, or 27 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| GSK561679 | 12.2091 |
| Placebo | 10.3813 |
Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01187511)
Timeframe: 90 minutes after the beginning of script presentation, which occurred on Day 25, 26, or 27 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| GSK561679 | 13.1376 |
| Placebo | 10.0004 |
Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01187511)
Timeframe: 100 minutes after the beginning of the Trier/cue-reactivity procedure, which occurred on Day 21 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| GSK561679 | 12.977 |
| Placebo | 12.0475 |
Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01187511)
Timeframe: 15 minutes prior to the beginning of the Trier/cue-reactivity procedure, which occurred on Day 21 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| GSK561679 | 15.1645 |
| Placebo | 12.0116 |
Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01187511)
Timeframe: 20 minutes after the beginning of the Trier/cue-reactivity procedure, which occurred on Day 21 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| GSK561679 | 18.4145 |
| Placebo | 15.2497 |
Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01187511)
Timeframe: 40 minutes after the beginning of the Trier/cue-reactivity procedure, which occurred on Day 21 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| GSK561679 | 20.352 |
| Placebo | 18.0116 |
Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01187511)
Timeframe: 70 minutes after the beginning of the Trier/cue-reactivity procedure, which occurred on Day 21 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| GSK561679 | 13.7895 |
| Placebo | 13.0592 |
Anxiety symptoms were measured using the Comprehensive Psychopathological Rating Scale (CPRS). The CPRS is an 18-item interview-based instrument for assessing depression and anxiety. There are two 10-item subscales, the Montgomery-Asberg Depression Rating Scale (MADRS) and the Brief Scale for Anxiety (BSA). Each subscale ranges from 0 (lowest symptom severity) to 60 (highest symptom severity). (NCT01187511)
Timeframe: Day 1 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| GSK561679 | 7.8582 |
| Placebo | 8.7076 |
Anxiety symptoms were measured using the Comprehensive Psychopathological Rating Scale (CPRS). The CPRS is an 18-item interview-based instrument for assessing depression and anxiety. There are two 10-item subscales, the Montgomery-Asberg Depression Rating Scale (MADRS) and the Brief Scale for Anxiety (BSA). Each subscale ranges from 0 (lowest symptom severity) to 60 (highest symptom severity). (NCT01187511)
Timeframe: Day 11 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| GSK561679 | 6.4777 |
| Placebo | 7.041 |
Anxiety symptoms were measured using the Comprehensive Psychopathological Rating Scale (CPRS). The CPRS is an 18-item interview-based instrument for assessing depression and anxiety. There are two 10-item subscales, the Montgomery-Asberg Depression Rating Scale (MADRS) and the Brief Scale for Anxiety (BSA). Each subscale ranges from 0 (lowest symptom severity) to 60 (highest symptom severity). (NCT01187511)
Timeframe: Day 14 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| GSK561679 | 6.5443 |
| Placebo | 6.6122 |
Anxiety symptoms were measured using the Comprehensive Psychopathological Rating Scale (CPRS). The CPRS is an 18-item interview-based instrument for assessing depression and anxiety. There are two 10-item subscales, the Montgomery-Asberg Depression Rating Scale (MADRS) and the Brief Scale for Anxiety (BSA). Each subscale ranges from 0 (lowest symptom severity) to 60 (highest symptom severity). (NCT01187511)
Timeframe: Day 18 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| GSK561679 | 6.011 |
| Placebo | 5.4219 |
Anxiety symptoms were measured using the Comprehensive Psychopathological Rating Scale (CPRS). The CPRS is an 18-item interview-based instrument for assessing depression and anxiety. There are two 10-item subscales, the Montgomery-Asberg Depression Rating Scale (MADRS) and the Brief Scale for Anxiety (BSA). Each subscale ranges from 0 (lowest symptom severity) to 60 (highest symptom severity). (NCT01187511)
Timeframe: Day 21 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| GSK561679 | 6.611 |
| Placebo | 5.7835 |
Anxiety symptoms were measured using the Comprehensive Psychopathological Rating Scale (CPRS). The CPRS is an 18-item interview-based instrument for assessing depression and anxiety. There are two 10-item subscales, the Montgomery-Asberg Depression Rating Scale (MADRS) and the Brief Scale for Anxiety (BSA). Each subscale ranges from 0 (lowest symptom severity) to 60 (highest symptom severity). (NCT01187511)
Timeframe: Day 25 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| GSK561679 | 5.3112 |
| Placebo | 5.1362 |
Anxiety symptoms were measured using the Comprehensive Psychopathological Rating Scale (CPRS). The CPRS is an 18-item interview-based instrument for assessing depression and anxiety. There are two 10-item subscales, the Montgomery-Asberg Depression Rating Scale (MADRS) and the Brief Scale for Anxiety (BSA). Each subscale ranges from 0 (lowest symptom severity) to 60 (highest symptom severity). (NCT01187511)
Timeframe: Day 28 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| GSK561679 | 7.2231 |
| Placebo | 4.5648 |
Anxiety symptoms were measured using the Comprehensive Psychopathological Rating Scale (CPRS). The CPRS is an 18-item interview-based instrument for assessing depression and anxiety. There are two 10-item subscales, the Montgomery-Asberg Depression Rating Scale (MADRS) and the Brief Scale for Anxiety (BSA). Each subscale ranges from 0 (lowest symptom severity) to 60 (highest symptom severity). (NCT01187511)
Timeframe: Day 32 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| GSK561679 | 5.2365 |
| Placebo | 4.2791 |
Anxiety symptoms were measured using the Comprehensive Psychopathological Rating Scale (CPRS). The CPRS is an 18-item interview-based instrument for assessing depression and anxiety. There are two 10-item subscales, the Montgomery-Asberg Depression Rating Scale (MADRS) and the Brief Scale for Anxiety (BSA). Each subscale ranges from 0 (lowest symptom severity) to 60 (highest symptom severity). (NCT01187511)
Timeframe: Day 4 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| GSK561679 | 6.6777 |
| Placebo | 5.9457 |
Anxiety symptoms were measured using the Comprehensive Psychopathological Rating Scale (CPRS). The CPRS is an 18-item interview-based instrument for assessing depression and anxiety. There are two 10-item subscales, the Montgomery-Asberg Depression Rating Scale (MADRS) and the Brief Scale for Anxiety (BSA). Each subscale ranges from 0 (lowest symptom severity) to 60 (highest symptom severity). (NCT01187511)
Timeframe: Day 7 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| GSK561679 | 6.6078 |
| Placebo | 6.66 |
Depression symptoms were measured using the Comprehensive Psychopathological Rating Scale (CPRS). The CPRS is an 18-item interview-based instrument for assessing depression and anxiety. There are two 10-item subscales, the Montgomery-Asberg Depression Rating Scale (MADRS) and the Brief Scale for Anxiety (BSA). Each subscale ranges from 0 (lowest symptom severity) to 60 (highest symptom severity). (NCT01187511)
Timeframe: Day 1 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| GSK561679 | 10.002 |
| Placebo | 8.7759 |
Depression symptoms were measured using the Comprehensive Psychopathological Rating Scale (CPRS). The CPRS is an 18-item interview-based instrument for assessing depression and anxiety. There are two 10-item subscales, the Montgomery-Asberg Depression Rating Scale (MADRS) and the Brief Scale for Anxiety (BSA). Each subscale ranges from 0 (lowest symptom severity) to 60 (highest symptom severity). (NCT01187511)
Timeframe: Day 11 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| GSK561679 | 6.3187 |
| Placebo | 6.2997 |
Depression symptoms were measured using the Comprehensive Psychopathological Rating Scale (CPRS). The CPRS is an 18-item interview-based instrument for assessing depression and anxiety. There are two 10-item subscales, the Montgomery-Asberg Depression Rating Scale (MADRS) and the Brief Scale for Anxiety (BSA). Each subscale ranges from 0 (lowest symptom severity) to 60 (highest symptom severity). (NCT01187511)
Timeframe: Day 14 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| GSK561679 | 7.6521 |
| Placebo | 8.0633 |
Depression symptoms were measured using the Comprehensive Psychopathological Rating Scale (CPRS). The CPRS is an 18-item interview-based instrument for assessing depression and anxiety. There are two 10-item subscales, the Montgomery-Asberg Depression Rating Scale (MADRS) and the Brief Scale for Anxiety (BSA). Each subscale ranges from 0 (lowest symptom severity) to 60 (highest symptom severity). (NCT01187511)
Timeframe: Day 18 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| GSK561679 | 8.0521 |
| Placebo | 6.5855 |
Depression symptoms were measured using the Comprehensive Psychopathological Rating Scale (CPRS). The CPRS is an 18-item interview-based instrument for assessing depression and anxiety. There are two 10-item subscales, the Montgomery-Asberg Depression Rating Scale (MADRS) and the Brief Scale for Anxiety (BSA). Each subscale ranges from 0 (lowest symptom severity) to 60 (highest symptom severity). (NCT01187511)
Timeframe: Day 21 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| GSK561679 | 7.0521 |
| Placebo | 5.9353 |
Depression symptoms were measured using the Comprehensive Psychopathological Rating Scale (CPRS). The CPRS is an 18-item interview-based instrument for assessing depression and anxiety. There are two 10-item subscales, the Montgomery-Asberg Depression Rating Scale (MADRS) and the Brief Scale for Anxiety (BSA). Each subscale ranges from 0 (lowest symptom severity) to 60 (highest symptom severity). (NCT01187511)
Timeframe: Day 25 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| GSK561679 | 4.8092 |
| Placebo | 4.9188 |
Depression symptoms were measured using the Comprehensive Psychopathological Rating Scale (CPRS). The CPRS is an 18-item interview-based instrument for assessing depression and anxiety. There are two 10-item subscales, the Montgomery-Asberg Depression Rating Scale (MADRS) and the Brief Scale for Anxiety (BSA). Each subscale ranges from 0 (lowest symptom severity) to 60 (highest symptom severity). (NCT01187511)
Timeframe: Day 28 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| GSK561679 | 7.149 |
| Placebo | 4.2997 |
Depression symptoms were measured using the Comprehensive Psychopathological Rating Scale (CPRS). The CPRS is an 18-item interview-based instrument for assessing depression and anxiety. There are two 10-item subscales, the Montgomery-Asberg Depression Rating Scale (MADRS) and the Brief Scale for Anxiety (BSA). Each subscale ranges from 0 (lowest symptom severity) to 60 (highest symptom severity). (NCT01187511)
Timeframe: Day 32 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| GSK561679 | 4.8071 |
| Placebo | 4.2045 |
Depression symptoms were measured using the Comprehensive Psychopathological Rating Scale (CPRS). The CPRS is an 18-item interview-based instrument for assessing depression and anxiety. There are two 10-item subscales, the Montgomery-Asberg Depression Rating Scale (MADRS) and the Brief Scale for Anxiety (BSA). Each subscale ranges from 0 (lowest symptom severity) to 60 (highest symptom severity). (NCT01187511)
Timeframe: Day 4 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| GSK561679 | 8.2521 |
| Placebo | 7.1569 |
Depression symptoms were measured using the Comprehensive Psychopathological Rating Scale (CPRS). The CPRS is an 18-item interview-based instrument for assessing depression and anxiety. There are two 10-item subscales, the Montgomery-Asberg Depression Rating Scale (MADRS) and the Brief Scale for Anxiety (BSA). Each subscale ranges from 0 (lowest symptom severity) to 60 (highest symptom severity). (NCT01187511)
Timeframe: Day 7 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| GSK561679 | 6.6366 |
| Placebo | 6.9188 |
Alcohol craving was measured using the Penn Alcohol Craving Scale (PACS). The PACS is a five-item self-administered instrument for assessing alcohol craving over the course of the past week. The score ranges from 0 (lowest craving value) to 30 (highest craving value). (NCT01187511)
Timeframe: Day 1 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| GSK561679 | 9.5572 |
| Placebo | 12.2152 |
Alcohol craving was measured using the Penn Alcohol Craving Scale (PACS). The PACS is a five-item self-administered instrument for assessing alcohol craving over the course of the past week. The score ranges from 0 (lowest craving value) to 30 (highest craving value). (NCT01187511)
Timeframe: Day 11 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| GSK561679 | 7.7 |
| Placebo | 8.8468 |
Alcohol craving was measured using the Penn Alcohol Craving Scale (PACS). The PACS is a five-item self-administered instrument for assessing alcohol craving over the course of the past week. The score ranges from 0 (lowest craving value) to 30 (highest craving value). (NCT01187511)
Timeframe: Day 14 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| GSK561679 | 5.7 |
| Placebo | 7.3205 |
Alcohol craving was measured using the Penn Alcohol Craving Scale (PACS). The PACS is a five-item self-administered instrument for assessing alcohol craving over the course of the past week. The score ranges from 0 (lowest craving value) to 30 (highest craving value). (NCT01187511)
Timeframe: Day 18 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| GSK561679 | 6.2715 |
| Placebo | 6.9521 |
Alcohol craving was measured using the Penn Alcohol Craving Scale (PACS). The PACS is a five-item self-administered instrument for assessing alcohol craving over the course of the past week. The score ranges from 0 (lowest craving value) to 30 (highest craving value). (NCT01187511)
Timeframe: Day 21 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| GSK561679 | 5.2715 |
| Placebo | 6.531 |
Alcohol craving was measured using the Penn Alcohol Craving Scale (PACS). The PACS is a five-item self-administered instrument for assessing alcohol craving over the course of the past week. The score ranges from 0 (lowest craving value) to 30 (highest craving value). (NCT01187511)
Timeframe: Day 25 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| GSK561679 | 4.6286 |
| Placebo | 6.6363 |
Alcohol craving was measured using the Penn Alcohol Craving Scale (PACS). The PACS is a five-item self-administered instrument for assessing alcohol craving over the course of the past week. The score ranges from 0 (lowest craving value) to 30 (highest craving value). (NCT01187511)
Timeframe: Day 28 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| GSK561679 | 3.6083 |
| Placebo | 6.5836 |
Alcohol craving was measured using the Penn Alcohol Craving Scale (PACS). The PACS is a five-item self-administered instrument for assessing alcohol craving over the course of the past week. The score ranges from 0 (lowest craving value) to 30 (highest craving value). (NCT01187511)
Timeframe: Day 32 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| GSK561679 | 3.7666 |
| Placebo | 6.531 |
Alcohol craving was measured using the Penn Alcohol Craving Scale (PACS). The PACS is a five-item self-administered instrument for assessing alcohol craving over the course of the past week. The score ranges from 0 (lowest craving value) to 30 (highest craving value). (NCT01187511)
Timeframe: Day 4 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| GSK561679 | 7.9858 |
| Placebo | 9.7942 |
Alcohol craving was measured using the Penn Alcohol Craving Scale (PACS). The PACS is a five-item self-administered instrument for assessing alcohol craving over the course of the past week. The score ranges from 0 (lowest craving value) to 30 (highest craving value). (NCT01187511)
Timeframe: Day 7 of the treatment period
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| GSK561679 | 8.1286 |
| Placebo | 8.7942 |
Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01227980)
Timeframe: 15 minutes after the beginning of script presentation, which occurred on Day 24, 25, or 26 of the treatment period
| Intervention | Units on a scale (Mean) |
|---|---|
| Pexacerfont | 16.6 |
| Placebo | 12.9 |
Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01227980)
Timeframe: 15 minutes prior to the beginning of script presentation, which occurred on Day 24, 25, or 26 of the treatment period
| Intervention | Units on a scale (Mean) |
|---|---|
| Pexacerfont | 12.7 |
| Placebo | 10.7 |
Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01227980)
Timeframe: 30 minutes after the beginning of script presentation, which occurred on Day 24, 25, or 26 of the treatment period
| Intervention | units on a scale (Mean) |
|---|---|
| Pexacerfont | 16.5 |
| Placebo | 11.8 |
Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01227980)
Timeframe: 45 minutes after the beginning of script presentation, which occurred on Day 24, 25, or 26 of the treatment period
| Intervention | units on a scale (Mean) |
|---|---|
| Pexacerfont | 15 |
| Placebo | 12.1 |
Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01227980)
Timeframe: 5 minutes after the beginning of script presentation, which occurred on Day 24, 25, or 26 of the treatment period
| Intervention | units on a scale (Mean) |
|---|---|
| Pexacerfont | 18.7 |
| Placebo | 14.5 |
Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01227980)
Timeframe: 60 minutes after the beginning of script presentation, which occurred on Day 24, 25, or 26 of the treatment period
| Intervention | units on a scale (Mean) |
|---|---|
| Pexacerfont | 13.7 |
| Placebo | 12.3 |
Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01227980)
Timeframe: 75 minutes after the beginning of script presentation, which occurred on Day 24, 25, or 26 of the treatment period
| Intervention | units on a scale (Mean) |
|---|---|
| Pexacerfont | 13.5 |
| Placebo | 12 |
Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01227980)
Timeframe: 90 minutes after the beginning of script presentation, which occurred on Day 24, 25, or 26 of the treatment period
| Intervention | units on a scale (Mean) |
|---|---|
| Pexacerfont | 13.7 |
| Placebo | 11.7 |
Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01227980)
Timeframe: 15 minutes after the beginning of script presentation, which occurred on Day 24, 25, or 26 of the treatment period
| Intervention | units on a scale (Mean) |
|---|---|
| Pexacerfont | 16.8 |
| Placebo | 12.5 |
Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01227980)
Timeframe: 15 minutes prior to the beginning of script presentation, which occurred on Day 24, 25, or 26 of the treatment period
| Intervention | units on a scale (Mean) |
|---|---|
| Pexacerfont | 12.9 |
| Placebo | 10.2 |
Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01227980)
Timeframe: 30 minutes after the beginning of script presentation, which occurred on Day 24, 25, or 26 of the treatment period
| Intervention | units on a scale (Mean) |
|---|---|
| Pexacerfont | 15.3 |
| Placebo | 12.2 |
Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01227980)
Timeframe: 45 minutes after the beginning of script presentation, which occurred on Day 24, 25, or 26 of the treatment period
| Intervention | units on a scale (Mean) |
|---|---|
| Pexacerfont | 14.9 |
| Placebo | 11.6 |
Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01227980)
Timeframe: 5 minutes after the beginning of script presentation, which occurred on Day 24, 25, or 26 of the treatment period
| Intervention | units on a scale (Mean) |
|---|---|
| Pexacerfont | 17.8 |
| Placebo | 14.4 |
Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01227980)
Timeframe: 60 minutes after the beginning of script presentation, which occurred on Day 24, 25, or 26 of the treatment period
| Intervention | units on a scale (Mean) |
|---|---|
| Pexacerfont | 14.3 |
| Placebo | 11.6 |
Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01227980)
Timeframe: 75 minutes after the beginning of script presentation, which occurred on Day 24, 25, or 26 of the treatment period
| Intervention | units on a scale (Mean) |
|---|---|
| Pexacerfont | 14.9 |
| Placebo | 11.7 |
Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value). (NCT01227980)
Timeframe: 90 minutes after the beginning of script presentation, which occurred on Day 24, 25, or 26 of the treatment period
| Intervention | Units on a scale (Mean) |
|---|---|
| Pexacerfont | 14.6 |
| Placebo | 11.2 |
Alcohol craving was measured using the Penn Alcohol Craving Scale (PACS). It is a 5-item self-administered instrument that measures frequency, intensity, and duration of thoughts about drinking, along with ability to resist drinking. There is a single outcome score than ranges from 0 to 30, with 30 being the maximum amount of alcohol craving. (NCT00605904)
Timeframe: 180 minutes after the start of the infusion
| Intervention | Units on a scale (Mean) |
|---|---|
| Acamprosate | 3.460 |
| Placebo | 5.416 |
Alcohol craving was measured using the Penn Alcohol Craving Scale (PACS). It is a 5-item self-administered instrument that measures frequency, intensity, and duration of thoughts about drinking, along with ability to resist drinking. There is a single outcome score than ranges from 0 to 30, with 30 being the maximum amount of alcohol craving. (NCT00605904)
Timeframe: 180 minutes after the start of the infusion
| Intervention | Units on a scale (Mean) |
|---|---|
| Acamprosate | 1.704 |
| Placebo | 1.766 |
Alcohol craving was measured using the Penn Alcohol Craving Scale (PACS). It is a 5-item self-administered instrument that measures frequency, intensity, and duration of thoughts about drinking, along with ability to resist drinking. There is a single outcome score than ranges from 0 to 30, with 30 being the maximum amount of alcohol craving. (NCT00605904)
Timeframe: 180 minutes after the start of the infusion
| Intervention | Units on a scale (Mean) |
|---|---|
| Acamprosate | 3.613 |
| Placebo | 3.606 |
2 reviews available for ondansetron and Disease Models, Animal
| Article | Year |
|---|---|
Pharmacological treatment of alcohol dependence: target symptoms and target mechanisms.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Animals; Baclofen; Corticotropin-Releasing Hormone; Dis | 2006 |
Pharmacological treatment of alcohol dependence: target symptoms and target mechanisms.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Animals; Baclofen; Corticotropin-Releasing Hormone; Dis | 2006 |
Pharmacological treatment of alcohol dependence: target symptoms and target mechanisms.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Animals; Baclofen; Corticotropin-Releasing Hormone; Dis | 2006 |
Pharmacological treatment of alcohol dependence: target symptoms and target mechanisms.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Animals; Baclofen; Corticotropin-Releasing Hormone; Dis | 2006 |
Pharmacological treatment of alcohol dependence: target symptoms and target mechanisms.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Animals; Baclofen; Corticotropin-Releasing Hormone; Dis | 2006 |
Pharmacological treatment of alcohol dependence: target symptoms and target mechanisms.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Animals; Baclofen; Corticotropin-Releasing Hormone; Dis | 2006 |
Pharmacological treatment of alcohol dependence: target symptoms and target mechanisms.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Animals; Baclofen; Corticotropin-Releasing Hormone; Dis | 2006 |
Pharmacological treatment of alcohol dependence: target symptoms and target mechanisms.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Animals; Baclofen; Corticotropin-Releasing Hormone; Dis | 2006 |
Pharmacological treatment of alcohol dependence: target symptoms and target mechanisms.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Animals; Baclofen; Corticotropin-Releasing Hormone; Dis | 2006 |
The pharmacology of the 5-HT4 receptor.
Topics: 4-Aminobenzoic Acid; 5-Hydroxytryptophan; Animals; Anxiety; Arousal; Brain; Diazepam; Disease Models | 1993 |
69 other studies available for ondansetron and Disease Models, Animal
| Article | Year |
|---|---|
5-HT3 receptor antagonists. 3. Quinoline derivatives which may be effective in the therapy of irritable bowel syndrome.
Topics: Animals; Carboxylic Acids; Castor Oil; Colon; Colonic Diseases, Functional; Defecation; Diarrhea; Di | 1993 |
Novel serotonin type 3 receptor partial agonists for the potential treatment of irritable bowel syndrome.
Topics: Animals; Cell Line; Disease Models, Animal; Humans; Imidazoles; Indoles; Irritable Bowel Syndrome; M | 2011 |
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
Topics: Animals; Antiviral Agents; Artificial Intelligence; Chlorocebus aethiops; Disease Models, Animal; Dr | 2020 |
Autoradiographic labelling of 5-HT
Topics: Animals; Antiparkinson Agents; Disease Models, Animal; Dyskinesia, Drug-Induced; Levodopa; Ondansetr | 2022 |
Effects of ondansetron on apamin-sensitive small conductance calcium-activated potassium currents in pacing-induced failing rabbit hearts.
Topics: Action Potentials; Animals; Apamin; Cardiac Pacing, Artificial; Disease Models, Animal; Heart Failur | 2020 |
Mild Traumatic Brain Injury Causes Nociceptive Sensitization through Spinal Chemokine Upregulation.
Topics: 5,7-Dihydroxytryptamine; Animals; Benzamides; Brain Injuries, Traumatic; Chemokine CXCL1; Chemokine | 2019 |
Tropisetron ameliorates cyclophosphamide-induced hemorrhagic cystitis in rats.
Topics: alpha7 Nicotinic Acetylcholine Receptor; Animals; Anti-Inflammatory Agents; Cyclophosphamide; Cystit | 2020 |
Role of peripheral 5-HT
Topics: Animals; Carrageenan; Disease Models, Animal; Hyperalgesia; Male; Mice; Nociception; Ondansetron; Pa | 2021 |
Serotonin Plays a Key Role in the Development of Opioid-Induced Hyperalgesia in Mice.
Topics: Analgesics, Opioid; Animals; Astrocytes; Disease Models, Animal; Hyperalgesia; Male; Mice; Mice, Inb | 2021 |
Effects of 5-HT
Topics: Acute Kidney Injury; Aged; Animals; Benzimidazoles; Cisplatin; Disease Models, Animal; Female; Grani | 2021 |
Co-administration of Cyclosporin A and Ondansetron decreases transient local cerebral ischemic injury in the mouse.
Topics: Animals; Cerebrovascular Circulation; Cyclosporine; Disease Models, Animal; Drug Therapy, Combinatio | 2017 |
New
Topics: Analgesics; Animals; Behavior, Animal; Capsaicin; Coffee; Disease Models, Animal; Female; Formaldehy | 2018 |
LASSBio-1586, an N-acylhydrazone derivative, attenuates nociceptive behavior and the inflammatory response in mice.
Topics: Acetic Acid; Analgesics; Animals; Anti-Inflammatory Agents, Non-Steroidal; Arachidonic Acid; Carrage | 2018 |
Modality selective roles of pro-nociceptive spinal 5-HT
Topics: Animals; Disease Models, Animal; Ketanserin; Male; Membrane Potentials; Neural Pathways; Neuralgia; | 2018 |
Effect of low doses of cannabidiolic acid and ondansetron on LiCl-induced conditioned gaping (a model of nausea-induced behaviour) in rats.
Topics: Animals; Antiemetics; Antineoplastic Agents; Behavior, Animal; Cannabinoids; Conditioning, Psycholog | 2013 |
Descending facilitation maintains long-term spontaneous neuropathic pain.
Topics: Afferent Pathways; Anesthetics, Local; Animals; Benzodiazepines; Conditioning, Operant; Disease Mode | 2013 |
Zonisamide: Antihyperalgesic efficacy, the role of serotonergic receptors on efficacy in a rat model for painful diabetic neuropathy.
Topics: Animals; Anticonvulsants; Carbamazepine; Diabetic Neuropathies; Disease Models, Animal; Dose-Respons | 2014 |
Acute and chronic administration of a low-dose combination of topiramate and ondansetron reduces ethanol's reinforcing effects in male alcohol preferring (P) rats.
Topics: Alcohol-Related Disorders; Animals; Behavior, Animal; Disease Models, Animal; Drug Administration Sc | 2014 |
Fluvoxamine alleviates seizure activity and downregulates hippocampal GAP-43 expression in pentylenetetrazole-kindled mice: role of 5-HT3 receptors.
Topics: Animals; Anticonvulsants; Cell Death; Disease Models, Animal; Fluvoxamine; GAP-43 Protein; Hippocamp | 2015 |
A 5-HT3 receptor antagonist potentiates the behavioral, neurochemical and electrophysiological actions of an SSRI antidepressant.
Topics: Animals; Depression; Disease Models, Animal; Dorsal Raphe Nucleus; Drug Synergism; Electrophysiologi | 2015 |
5-HT3 receptors antagonists reduce serotonin-induced scratching in mice.
Topics: Animals; Antipruritics; Behavior, Animal; Disease Models, Animal; Dose-Response Relationship, Drug; | 2015 |
Diffuse noxious inhibitory controls and nerve injury: restoring an imbalance between descending monoamine inhibitions and facilitations.
Topics: Action Potentials; Adrenergic alpha-2 Receptor Antagonists; Analysis of Variance; Animals; Biogenic | 2015 |
[Effect of Ju-Pi-Tang on Cisplatin-induced Emetic Model in Minks].
Topics: Animals; Antiemetics; Aprepitant; Brain; Cisplatin; Disease Models, Animal; Drugs, Chinese Herbal; I | 2015 |
Galanin-Mediated Behavioural Hyperalgesia from the Dorsomedial Nucleus of the Hypothalamus Involves Two Independent Descending Pronociceptive Pathways.
Topics: Animals; Arthritis; Behavior, Animal; Disease Models, Animal; Electrophysiology; Galanin; Glutamic A | 2015 |
Differential effects of a short-term high-fat diet in an animal model of depression in rats treated with the 5-HT3 receptor antagonist, ondansetron, the 5-HT3 receptor agonist, 2-methyl-5-HT, and the SSRI, fluoxetine.
Topics: Animals; Depression; Diet, High-Fat; Disease Models, Animal; Fluoxetine; Male; Ondansetron; Rats; Ra | 2016 |
α-Terpineol, a monoterpene alcohol, complexed with β-cyclodextrin exerts antihyperalgesic effect in animal model for fibromyalgia aided with docking study.
Topics: Analgesics; Animals; Behavior, Animal; beta-Cyclodextrins; Binding Sites; Cyclohexane Monoterpenes; | 2016 |
Pharmacological manipulation of immune-induced food aversion in rats.
Topics: Animals; Avoidance Learning; Capillary Permeability; Cell Degranulation; Conditioning, Psychological | 2009 |
Effect of central administration of ondansetron, a 5-hydroxytryptamine-3 receptor antagonist on gastric and duodenal ulcers.
Topics: Animals; Brain; Disease Models, Animal; Dose-Response Relationship, Drug; Duodenal Ulcer; Gastric Ac | 2009 |
Ondansetron and fluoxetine reduce sleep apnea in mice lacking monoamine oxidase A.
Topics: Analysis of Variance; Animals; Disease Models, Animal; Dose-Response Relationship, Drug; Fluoxetine; | 2009 |
5-HT2 receptors modulate excitatory neurotransmission to cardiac vagal neurons within the nucleus ambiguus evoked during and after hypoxia.
Topics: Animals; Disease Models, Animal; Excitatory Postsynaptic Potentials; Heart; Hypoxia, Brain; Ketanser | 2009 |
How right is the righting reflex? The risk of false positives in neuroprotection studies using behavioral measures to certify forebrain ischemia.
Topics: Animals; Cell Survival; Disease Models, Animal; Dose-Response Relationship, Drug; Male; Memory Disor | 2010 |
Moringa oleifera induced potentiation of serotonin release by 5-HT(3) receptors in experimental ulcer model.
Topics: Animals; Anti-Ulcer Agents; Aspirin; Disease Models, Animal; Enterochromaffin Cells; Female; Male; M | 2011 |
Spinal cord mechanisms mediating behavioral hyperalgesia induced by neurokinin-1 tachykinin receptor activation in the rostral ventromedial medulla.
Topics: Animals; Behavior, Animal; Bridged Bicyclo Compounds, Heterocyclic; Disease Models, Animal; Dizocilp | 2010 |
Ondansetron does not block paracetamol-induced analgesia in a mouse model of fracture pain.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Animals; Antiemetics; Disease Models, Animal; Drug Interact | 2011 |
Ondansetron attenuates hepatic injury via p38 MAPK-dependent pathway in a rat haemorrhagic shock model.
Topics: Alanine Transaminase; Animals; Aspartate Aminotransferases; Chemokine CXCL1; Chemokine CXCL2; Cytoki | 2011 |
Severity of drinking as a predictor of efficacy of the combination of ondansetron and topiramate in rat models of ethanol consumption and relapse.
Topics: Alcohol Drinking; Alcoholism; Animals; Behavior, Animal; Disease Models, Animal; Drug Therapy, Combi | 2011 |
Ondansetron interferes with unconditioned lying-on belly and acquisition of conditioned gaping induced by LiCl as models of nausea-induced behaviors in rats.
Topics: Analysis of Variance; Animals; Antiemetics; Avoidance Learning; Conditioning, Classical; Disease Mod | 2012 |
Distinct mechanisms underlying pronociceptive effects of opioids.
Topics: 2-Amino-5-phosphonovalerate; Analgesics, Opioid; Animals; Disease Models, Animal; Dose-Response Rela | 2011 |
Effects of diphenyl diselenide on depressive-like behavior in ovariectomized mice submitted to subchronic stress: involvement of the serotonergic system.
Topics: Animals; Antidepressive Agents; Benzene Derivatives; Cerebral Cortex; Depression; Disease Models, An | 2012 |
Ondansetron reverses antihypersensitivity from clonidine in rats after peripheral nerve injury: role of γ-aminobutyric acid in α2-adrenoceptor and 5-HT3 serotonin receptor analgesia.
Topics: Adrenergic alpha-2 Receptor Agonists; Analgesia; Animals; Clonidine; Disease Models, Animal; gamma-A | 2012 |
Differential effects of 5-HT3 receptor antagonist on lipid profile in spontaneously hypertensive rat and chromosome 8 congenic strain.
Topics: Animals; Animals, Congenic; Chromosomes, Mammalian; Disease Models, Animal; Glucose Intolerance; Hyp | 2012 |
Ondansetron given in the acute withdrawal from a repeated cocaine sensitization dosing regimen reverses the expression of sensitization and inhibits self-administration.
Topics: Acute Disease; Animals; Behavior, Animal; Brain; Cocaine; Cocaine-Related Disorders; Disease Models, | 2002 |
[A new vomiting animal model--mink].
Topics: Animals; Antiemetics; Apomorphine; Cisplatin; Copper Sulfate; Disease Models, Animal; Male; Metoclop | 2003 |
Methylnaltrexone prevents morphine-induced kaolin intake in the rat.
Topics: Animals; Antiemetics; Diet; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Therapy, | 2004 |
Spinal-supraspinal serotonergic circuits regulating neuropathic pain and its treatment with gabapentin.
Topics: Action Potentials; Amines; Analgesics; Analysis of Variance; Animals; Behavior, Animal; Cell Count; | 2005 |
Delta-9-tetrahydrocannabinol and cannabidiol, but not ondansetron, interfere with conditioned retching reactions elicited by a lithium-paired context in Suncus murinus: An animal model of anticipatory nausea and vomiting.
Topics: Analysis of Variance; Animals; Antiemetics; Association Learning; Cannabidiol; Cannabinoids; Conditi | 2006 |
Evidence of a role for descending serotonergic facilitation in a rat model of cancer-induced bone pain.
Topics: Animals; Behavior, Animal; Bone Diseases; Cell Line, Tumor; Disease Models, Animal; Dose-Response Re | 2006 |
Interaction between tramadol and two anti-emetics on nociception and gastrointestinal transit in mice.
Topics: Analgesics, Opioid; Animals; Antiemetics; Disease Models, Animal; Dose-Response Relationship, Drug; | 2006 |
Value of mink vomit model in study of anti-emetic drugs.
Topics: Animals; Antiemetics; Apomorphine; Cisplatin; Copper Sulfate; Disease Models, Animal; Enterochromaff | 2006 |
Exposure to a lithium-paired context elicits gaping in rats: A model of anticipatory nausea.
Topics: Animals; Antiemetics; Conditioning, Operant; Disease Models, Animal; Dronabinol; Infusions, Intraven | 2006 |
Reversal of cocaine-induced behavioral sensitization and associated phosphorylation of the NR2B and GluR1 subunits of the NMDA and AMPA receptors.
Topics: Animals; Behavior, Addictive; Brain; Cocaine; Cocaine-Related Disorders; Disease Models, Animal; Dop | 2007 |
Determinants of drug brain uptake in a rat model of seizure-associated malformations of cortical development.
Topics: Animals; Anticonvulsants; Astrocytes; ATP Binding Cassette Transporter, Subfamily B, Member 1; Blood | 2006 |
Restraint stress stimulates colonic motility via central corticotropin-releasing factor and peripheral 5-HT3 receptors in conscious rats.
Topics: Animals; Capsaicin; Central Nervous System; Colon; Consciousness; Corticotropin-Releasing Hormone; D | 2007 |
The piglet as a suitable animal model for studying the delayed phase of cisplatin-induced emesis.
Topics: Animals; Cisplatin; Disease Models, Animal; Female; Granisetron; Male; Nausea; Ondansetron; Swine; T | 1995 |
Mast cell mediators and peritoneal adhesion formation in the rat.
Topics: Animals; Azepines; Disease Models, Animal; Histamine Antagonists; Leukotriene D4; Male; Mast Cells; | 1995 |
Effects of 5-HT3 receptor antagonists on models of acute and delayed emesis induced by cisplatin in the ferret.
Topics: Animals; Carbolines; Cisplatin; Disease Models, Animal; Emetics; Ferrets; Ondansetron; Serotonin Ant | 1994 |
Serotonin (5-HT)3-receptor antagonism of 4,5,6,7-tetrahydrobenzimidazole derivatives against 5-HT-induced bradycardia in anesthetized rats.
Topics: Animals; Benzimidazoles; Bradycardia; Colon; Disease Models, Animal; Dose-Response Relationship, Dru | 1994 |
Behavioural and pharmacological characterisation of the elevated "zero-maze" as an animal model of anxiety.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Anti-Anxiety Agents; Anxiety; Behavior, Animal; Chl | 1994 |
Pica in rats is analogous to emesis: an animal model in emesis research.
Topics: Animals; Antiemetics; Apomorphine; Cisplatin; Copper; Copper Sulfate; Disease Models, Animal; Domper | 1993 |
An experimental model to study intracranial hypertension-induced vomiting in conscious dogs.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Animals; Behavior, Animal; Disease Models | 1996 |
Antianxiety profile of ondansetron, a selective 5-HT3 antagonist, in a novel animal model.
Topics: Animals; Anti-Anxiety Agents; Anxiety; Behavior, Animal; Conflict, Psychological; Diazepam; Disease | 1997 |
Secretory pathways in Salmonella Typhimurium-induced fluid accumulation in the porcine small intestine.
Topics: Analysis of Variance; Animals; Cholera Toxin; Diarrhea; Dinoprostone; Disease Models, Animal; Electr | 1998 |
5-HT3 receptor antagonists ameliorate emesis in the ferret evoked by neutron or proton radiation.
Topics: Administration, Oral; Animals; Disease Models, Animal; Drug Evaluation, Preclinical; Ferrets; Gamma | 1999 |
Methotrexate produces delayed emesis in dogs: a potential model of delayed emesis induced by chemotherapy.
Topics: Animals; Antiemetics; Antineoplastic Agents; Cisplatin; Dexamethasone; Disease Models, Animal; Dogs; | 1999 |
The effects of ondansetron on sleep-disordered breathing in the English bulldog.
Topics: Administration, Intranasal; Animals; Behavior, Animal; Disease Models, Animal; Dogs; Drug Administra | 2001 |
Effects of alosetron on spontaneous migrating motor complexes in murine small and large bowel in vitro.
Topics: Animals; Carbolines; Colon; Colonic Diseases, Functional; Disease Models, Animal; Dose-Response Rela | 2001 |
Pica in mice as a new model for the study of emesis.
Topics: Animals; Antiemetics; Antineoplastic Agents; Carmine; Cisplatin; Disease Models, Animal; Eating; Fec | 2002 |
5-HT3 receptor antagonists reverse helpless behaviour in rats.
Topics: Analysis of Variance; Animals; Benzamides; Bridged Bicyclo Compounds; Bridged Bicyclo Compounds, Het | 1992 |
Antiemetic activity of the new 5-HT3 antagonist DAU 6215 in animal models of cancer chemotherapy and radiation.
Topics: Animals; Antiemetics; Benzimidazoles; Bridged Bicyclo Compounds; Bridged Bicyclo Compounds, Heterocy | 1991 |